Analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings per share (EPS) of $0.22 for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Sucampo Pharmaceuticals’ earnings. Sucampo Pharmaceuticals posted earnings of $0.23 per share in the same quarter last year, which indicates a negative year over year growth rate of 4.3%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, August 2nd.

According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full year earnings of $1.01 per share for the current fiscal year. For the next year, analysts expect that the business will post earnings of $1.04 per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by $0.05. Sucampo Pharmaceuticals had a net margin of 11.36% and a return on equity of 43.27%. The firm had revenue of $56.30 million for the quarter, compared to analysts’ expectations of $54.15 million. During the same period in the prior year, the company earned $0.21 EPS. The firm’s quarterly revenue was up 19.3% on a year-over-year basis.

A number of research firms have recently issued reports on SCMP. Jefferies Group LLC dropped their price target on Sucampo Pharmaceuticals from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, March 17th. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 4th. ValuEngine upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Maxim Group restated a “buy” rating and issued a $21.00 price target on shares of Sucampo Pharmaceuticals in a research note on Thursday, April 13th. Finally, Mizuho restated a “buy” rating and issued a $14.00 price target on shares of Sucampo Pharmaceuticals in a research note on Tuesday, April 4th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Sucampo Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $16.71.

Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded up 1.40% on Wednesday, hitting $10.85. The stock had a trading volume of 465,544 shares. The stock has a 50 day moving average of $10.28 and a 200-day moving average of $11.25. The stock has a market cap of $504.13 million, a PE ratio of 18.08 and a beta of 1.46. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.55.

TRADEMARK VIOLATION WARNING: “$0.22 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter” was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/12/0-22-eps-expected-for-sucampo-pharmaceuticals-inc-scmp-this-quarter.html.

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. bought a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter valued at $555,000. State Street Corp raised its position in shares of Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock valued at $7,882,000 after buying an additional 143,906 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Sucampo Pharmaceuticals by 7.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,559,433 shares of the biopharmaceutical company’s stock valued at $21,130,000 after buying an additional 103,986 shares during the period. Envestnet Asset Management Inc. acquired a new position in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $115,000. Finally, A.R.T. Advisors LLC acquired a new position in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $233,000. 57.00% of the stock is currently owned by hedge funds and other institutional investors.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.